breakthrough in Tuberculosis Treatment: New Regimens Offer Hope for Drug-Resistant TB
Tuberculosis (TB), one of the world’s deadliest infectious diseases, has long been a global health challenge, notably due to the rise of drug-resistant strains. Now, a groundbreaking international clinical trial has identified three new safe and effective drug regimens for treating rifampin-resistant TB, a form of the disease that resists the most potent first-line antibiotic.Published on January 30 in the New England Journal of Medicine, the study marks a significant leap forward in the fight against this persistent killer.
Led by researchers at Harvard Medical School and conducted under the endTB project—a collaboration among Partners In Health, Médecins Sans Frontières, and Interactive Research and Development—the trial tested five new, all-oral, nine-month regimens. These regimens combine two groundbreaking drugs, bedaquiline and delamanid, with older medications.The results? Three of the regimens proved highly effective,achieving success rates of 85 to 90 percent,compared to 81 percent in the control group.
A New Era for TB Treatment
Table of Contents
For decades, treating drug-resistant TB has been a grueling process. Patients often endured years of treatment, including daily injections and highly toxic medications with severe side effects. The new regimens not only shorten treatment but also eliminate the need for injections, offering a more tolerable and accessible option.
“This Harvard-led partnership among ngos, ministries of health, and other academic partners identified three new regimens that will make lifesaving care dramatically more accessible,” said Carole Mitnick, co-principal investigator of the trial and professor of global health and social medicine at Harvard Medical School. “We also resolved a critical question left open by pharmaceutical industry trials that brought bedaquiline and delamanid to market: How can these new drugs be used to shorten and simplify treatment while retaining efficacy?”
Expanding Access to Underserved Populations
The endTB trial enrolled 754 patients across seven countries—Georgia, India, Kazakhstan, lesotho, Pakistan, Peru, and South Africa—with a focus on improving treatment for rifampin-resistant TB. Notably, the study included populations often excluded from clinical trials, such as children, people living with HIV or hepatitis C, and pregnant women.
In august 2024, the World Health Association (WHO) added the three successful regimens to its list of recommended treatments for rifampin-resistant and multidrug-resistant TB (MDR-TB), extending these options to these underserved groups.
Affordability and Accessibility
Another major milestone is the affordability of these new treatments. Thanks to recent efforts to end patent exclusivity on bedaquiline,two of the endTB regimens and the WHO-recommended pretomanid-containing regimen can now be purchased for less than $500. This achievement meets a long-standing access target set by activists over a decade ago, ensuring that more people can benefit from these lifesaving treatments.
A Global Change
The endTB trial is part of a broader shift in how the world approaches TB treatment. By leveraging new drugs and innovative regimens,researchers are paving the way for shorter,safer,and more effective therapies. As Mitnick noted, “Until recently, poor treatment options and low-quality evidence made it difficult to stem the tide of preventable deaths from tuberculosis.”
With these advancements, the fight against TB is entering a new era—one where hope and healing are within reach for millions.
| Key Highlights of the endTB Trial |
|—————————————|
| Regimens Tested: 5 all-oral, 9-month combinations of bedaquiline, delamanid, and older drugs |
| Success Rates: 85-90% for new regimens vs. 81% for control group |
| Included Populations: Children, HIV/Hepatitis C patients, pregnant women |
| Cost: Less than $500 per regimen |
| WHO Approval: Added to treatment guidelines in August 2024 |
For more details on the study, visit the New England journal of Medicine here.
Breakthrough in Tuberculosis Treatment: New Regimens Offer hope for Drug-Resistant TB
Tuberculosis (TB),one of the world’s deadliest infectious diseases,has long posed meaningful global health challenges,especially due to the rise of drug-resistant strains.A groundbreaking international clinical trial, the endTB project, has identified three new safe and effective drug regimens for treating rifampin-resistant TB, a form of the disease that resists the most potent first-line antibiotic. Published in the New England Journal of Medicine, the study represents a significant leap forward in the fight against this persistent killer. We sat down with Dr. Elena Martinez, a leading infectious disease specialist and researcher involved in the trial, to discuss the implications of this breakthrough.
1. The Significance of the endTB Trial
Senior Editor: Dr. Martinez, thank you for joining us. Can you start by explaining why the endTB trial is such a pivotal moment in TB treatment?
Dr. Elena Martinez: Absolutely. The endTB trial is transformative as it addresses one of the most pressing challenges in TB care: the treatment of rifampin-resistant TB, which has traditionally been lengthy, toxic, and challenging to access. For years, patients endured up to two years of treatment, including painful daily injections and medications with severe side effects. This trial tested five all-oral, nine-month regimens combining newer drugs like bedaquiline and delamanid with older medications. Three of thes regimens achieved success rates of 85 to 90 percent, compared to 81 percent in the control group. This is a game-changer because it offers shorter, safer, and more effective treatment options.
2. Expanding Access to Underserved Populations
Senior Editor: The trial included populations frequently enough excluded from clinical trials, such as children, pregnant women, and people living with HIV or hepatitis C. Why was this inclusion so critical?
Dr. Elena Martinez: Historically, these groups have been underrepresented in clinical research, leading to gaps in data and limited treatment options for them. By including children,pregnant women,and individuals with comorbidities like HIV and hepatitis C,the endTB trial ensures that the findings are relevant to a broader population. This inclusivity is crucial because TB disproportionately affects marginalized communities, and equitable access to effective treatments is essential for global health equity. The world Health Association’s decision to add these regimens to its treatment guidelines in August 2024 further emphasizes their importance for these underserved groups.
3. Affordability and Global Impact
Senior Editor: One of the most remarkable aspects of this breakthrough is the affordability of the new regimens. how did the trial achieve this milestone?
Dr.Elena Martinez: Affordability has been a key focus of the endTB project from the outset.Thanks to concerted efforts to end patent exclusivity on bedaquiline, two of the endTB regimens and the WHO-recommended pretomanid-containing regimen can now be purchased for less than $500. This meets a long-standing access target set by activists over a decade ago. By reducing costs, we can ensure that these lifesaving treatments reach the people who need them most, particularly in low- and middle-income countries where the burden of drug-resistant TB is highest.
4. The Future of TB Treatment
Senior Editor: What does this breakthrough mean for the future of TB treatment globally?
Dr. Elena martinez: This trial represents a turning point in the fight against TB.For decades, poor treatment options and low-quality evidence made it difficult to address the growing burden of drug-resistant TB. The endTB trial demonstrates that with innovative research and collaboration, we can develop shorter, safer, and more effective therapies. This progress also underscores the importance of partnerships among NGOs,ministries of health,and academic institutions to tackle complex global health challenges. Moving forward, these advancements offer hope that we can substantially reduce the incidence of TB and save millions of lives.
Conclusion
The endTB trial marks a historic milestone in the fight against tuberculosis, offering new hope for millions of people affected by drug-resistant TB. With shorter, safer, and more affordable treatment options, this breakthrough has the potential to transform global health efforts and bring us closer to eradicating one of the world’s deadliest infectious diseases. As Dr. Elena Martinez highlighted, the trial’s success is a testament to the power of innovation, collaboration, and a commitment to equitable access to care.
